The Exeter-based ecommerce intelligence platform has raised £1.1m in a round led by Mercia Ventures alongside angel backing.
"At Distil, we are passionate about the power of data. It is the lifeblood of any business, shaping the landscape of industries around us. However, to truly harness its potential and transform it into a strategic asset, the way we approach and manage data must evolve. This is the driving force behind Distil.ai. Our mission is simple – if you want your data to guide your strategy, empower your marketing, and boost your profits, it’s time to start ‘Distiling’ it. We’ve filled Distil with powerful algorithms to provide a clear view of your business’s performance. With the support of our partners in this funding round, we’re set to accelerate the shift towards a more insightful and efficient future."
The financing was backed by Delin Ventures, AlbionVC, Playfair Capital and 11.2 Capital to support international growth and research programmes.
"We developed the uMed platform to help healthcare professionals more easily and efficiently run patient research and targeted care programmes at scale, improving outcomes for patients by mitigating care gaps and accelerating research. Our groundbreaking patient cohorts give researchers access to unique data and insights, accelerating development and access to new therapies, while dramatically reducing the cost of finding, engaging and collecting prospective data from patients."
The seed round was backed by a trio of venture capital firms including Redseed, Monte Carlo Capital, and Altair.
"This significant investment is a testament to the hard work and dedication of our team, who work together diligently to bring a wealth of experience and professionalism to the table. Both my team and investors are all excited to see how this innovation shapes the industry."
AXA Venture Partners led the Series A round with backing from Seedcamp to help accelerate product development and international growth.
"We’re delighted to be partnering with AVP. We work heavily in the finance sector and we’re proud to partner with a household financial services brand. AVP is a perfect partner for us to grow within other regulated domains and geographies with AVP’s global reach."
The Cambridge-based synthetic gene provider raised the capital from Mercia Ventures to expand operations and develop its DNA synthesis platform.
"We are delighted to have closed this latest round of funding with Mercia, which provides further validation of Camena’s approach. The ability to read, write and manipulate DNA is the foundation of the synthetic biology value chain, yet developments in DNA synthesis have not kept pace with DNA sequencing and editing capabilities. Camena’s gSynth platform is revolutionising the DNA synthesis market by unlocking access to genes and accelerating discovery pipelines. As the focus on sustainability and supply-chain security become more acute, Camena is leading the way with a green synthesis technology and is already well positioned to serve this burgeoning market. The invention of next-generation DNA sequencing technologies transformed our ability to ‘read’ DNA. Our goal is to enable our customers to ‘write’ DNA with the same confidence and ease."
